抗血栓药物市场规模、份额、成长分析（按类型、药物类别、适应症、给药途径、最终用户、分销管道和地区）- 产业预测，2025 年至 2032 年

预计 2023 年全球抗血栓药物市场价值将达到 484 亿美元，并从 2024 年的 522.2 亿美元增长到 2032 年的 959.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.9%。

全球抗血栓药物市场受多种关键因素驱动，尤其是心血管疾病盛行率的上升、老年人口的扩大以及对新型口服抗凝血药物 (NOAC) 需求的不断增长。心房颤动和静脉血栓栓塞症(VTE) 等心血管疾病是全球主要的健康挑战，推动了对这些药物的巨大需求。此外，老年人口越来越容易患血栓性疾病，进一步扩大了患者族群。Dabigatran和利伐沙班等 NOAC 因其使用方便、药物交互作用和出血风险低而越来越受欢迎。此外，预防性医疗保健意识的不断增强也推动了此类药物的广泛应用。然而，出血风险、高昂的药价和严格的监管等挑战可能会阻碍市场成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 顾客购买行为分析

抗血栓药物市场规模（按类型及复合年增长率）（2025-2032）

• 市场概览
• Apixaban
• 德比加群
• 依度沙班
• 磺达肝癸钠
• 肝素
• Rivaroxaban

抗血栓药物市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概览
• 溶栓药物
• 抗血小板药物
• 抗凝血剂
• 其他的

抗血栓药物市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概览
• 心房颤动
• 中风
• 深层静脉栓塞症（DVT）
• 肺动脉栓塞（PE）
• 其他的

抗血栓药物市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概览
• 口服
• 注射
• 其他的

抗血栓药物市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 专科诊所
• 居家护理
• 其他的

抗血栓药物市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 网路药局
• 其他的

抗血栓药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Ireland）
• Sanofi（France）
• Pfizer Inc.（US）
• GlaxoSmithKline plc（UK）
• Novartis AG（Switzerland）
• Merck & Co., Inc.（US）
• Allergan（Ireland）
• AstraZeneca（UK）
• Johnson & Johnson Private Limited（US）
• Hikma Pharmaceuticals PLC（UK）
• Fresenius Kabi AG（Germany）
• Eisai Co., Ltd.（Japan）
• Bristol-Myers Squibb Company（US）
• Bayer AG（Germany）
• DAIICHI SANKYO COMPANY, LIMITED（Japan）

结论和建议

Global Antithrombotic Drugs Market size was valued at USD 48.4 billion in 2023 and is poised to grow from USD 52.22 billion in 2024 to USD 95.95 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).

The global market for antithrombotic drugs is being propelled by several influential factors, particularly the growing prevalence of cardiovascular diseases, an expanding geriatric population, and a heightened demand for novel oral anticoagulants (NOACs). Cardiovascular issues, including atrial fibrillation and venous thromboembolism, represent a leading global health challenge, driving significant demand for these medications. Moreover, the elderly demographic is increasingly susceptible to thrombotic disorders, further widening the patient pool. NOACs, such as dabigatran and rivaroxaban, are gaining traction for their convenience and lower risk of interactions and bleeding. Additionally, rising awareness regarding preventive healthcare is fostering greater adoption. However, challenges such as the risk of bleeding, the high cost of medications, and stringent regulatory hurdles could hinder market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antithrombotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antithrombotic Drugs Market Segments Analysis

Global Antithrombotic Drugs Market is segmented by Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Apixaban, Debigatran, Edoxaban, Fondaparinux, Heparin and Rivaroxaban. Based on Drug Class, the market is segmented into Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants and Others. Based on Indication, the market is segmented into Atrial Fibrillation, Stroke, Deep vein thrombosis (DVT), Pulmonary Embolism (PE) and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antithrombotic Drugs Market

The increasing incidence of cardiovascular conditions such as atrial fibrillation, deep vein thrombosis, and strokes has significantly boosted the demand for antithrombotic medications. Contributing factors include a rising population, sedentary lifestyles, and the prevalence of metabolic syndrome, all of which underscore the importance of anticoagulants and antiplatelet agents. These medications are essential not only for immediate treatment but also for the long-term management of cardiovascular risks. As awareness of these health issues grows and preventive measures become more vital, the antithrombotic drugs market is expected to expand further, catering to the urgent need for effective therapeutic solutions.

Restraints in the Global Antithrombotic Drugs Market

The Global Antithrombotic Drugs market faces significant limitations due to the increased risk of bleeding associated with these medications, particularly in elderly individuals or those with additional health conditions. This elevated risk complicates clinical decision-making and often necessitates continuous monitoring, adjustments in dosage, or even the cessation of treatment. Such safety concerns can diminish physicians' confidence and affect patient adherence, ultimately impacting overall market penetration and the long-term success of therapy. As a result, healthcare providers must carefully weigh the benefits and drawbacks, which may hinder the widespread adoption of antithrombotic treatments in various patient populations.

Market Trends of the Global Antithrombotic Drugs Market

The global antithrombotic drugs market is witnessing a notable trend towards next-generation targeted therapies that prioritize ultra-specificity in targeting coagulation factors. This innovative approach aims to minimize bleeding risks while maintaining sustained efficacy, catering to the urgent demand for safer treatment options. By precisely addressing pathological processes, these advanced therapies promise to enhance safety profiles compared to existing medications, facilitating personalized treatment strategies that effectively balance clot prevention with bleeding control. As healthcare professionals increasingly seek tailored solutions for patients, the adoption of these cutting-edge antithrombotic therapies is expected to drive market growth and transformation in patient care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Antithrombotic Drugs Market Size by Type & CAGR (2025-2032)

• Market Overview
• Apixaban
• Debigatran
• Edoxaban
• Fondaparinux
• Heparin
• Rivaroxaban

Global Antithrombotic Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Thrombolytic Drugs
• Anti-Platelet Drugs
• Anticoagulants
• Others

Global Antithrombotic Drugs Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Atrial Fibrillation
• Stroke
• Deep vein thrombosis (DVT)
• Pulmonary Embolism (PE)
• Others

Global Antithrombotic Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Others

Global Antithrombotic Drugs Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Antithrombotic Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Antithrombotic Drugs Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Private Limited (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations